Venetoclax in adult acute myeloid leukemia

Venetoclax in adult acute myeloid leukemia

Venetoclax is a potent inhibitor that specifically targets B-cell lymphoma-2 (BCL-2), which has been demonstrated to be effective in preclinical studies utilizing acute myeloid leukemia (AML) cell lines and xenograft models. Significant antileukemic activity was also observed in clinical trials, bot...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biomedicine & pharmacotherapy 2023-12, Vol.168, p.115820-115820, Article 115820
Hauptverfasser: Hu, Mengci, Li, Wenzhe, Zhang, Youshan, Liang, Caixia, Tan, Jie, Wang, Ya
Format: Artikel
Sprache:eng
Schlagworte:
Acute myeloid leukemia
Combinatorial regimens
Venetoclax
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 115820
container_issue
container_start_page 115820
container_title Biomedicine & pharmacotherapy
container_volume 168
creator Hu, Mengci
Li, Wenzhe
Zhang, Youshan
Liang, Caixia
Tan, Jie
Wang, Ya
description Venetoclax is a potent inhibitor that specifically targets B-cell lymphoma-2 (BCL-2), which has been demonstrated to be effective in preclinical studies utilizing acute myeloid leukemia (AML) cell lines and xenograft models. Significant antileukemic activity was also observed in clinical trials, both as a monotherapy and in combination with other drugs. This novel therapeutic approach has revolutionized the treatment prospects for AML patients with unfavorable prognoses and those who are unable to tolerate intensive chemotherapy. Nevertheless, further investigations are required to establish the optimal dosing, sequencing, and combinational strategies of venetoclax for AML treatments. Additionally, identifying biomarkers is crucial for predicting response and resistance to this targeted intervention. In this review, we provide an overview of venetoclax-based therapy for AML and explore potential avenues for future research.
doi_str_mv 10.1016/j.biopha.2023.115820
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2886598249</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0753332223016189</els_id><sourcerecordid>2886598249</sourcerecordid><originalsourceid>FETCH-LOGICAL-c385t-8ed44685a0b3b41fb866466c35af8367e7015ab862c4cde5db7a8d3c4bd2c68c3</originalsourceid><addsrcrecordid>eNp9kE1LxDAYhIMouK7-Aw89itCa72Yvgix-wYIX9RrS5C1mTZs1acX993apZ08Dw8zAPAhdElwRTOTNtmp83H2YimLKKkKEovgILchK4FJiXB-jBa4FKxmj9BSd5bzFGAvJ1AJdv0MPQ7TB_BS-L4wbw1AYOw5QdHsI0bsiwPgJnTfn6KQ1IcPFny7R28P96_qp3Lw8Pq_vNqVlSgylAse5VMLghjWctI2SkktpmTCtYrKGGhNhJpdabh0I19RGOWZ546iVyrIlupp3dyl-jZAH3flsIQTTQxyzpkpJsVKUr6Yon6M2xZwTtHqXfGfSXhOsD2j0Vs9o9AGNntFMtdu5BtONbw9JZ-uht-B8AjtoF_3_A7-nCG2O</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2886598249</pqid></control><display><type>article</type><title>Venetoclax in adult acute myeloid leukemia</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Access via ScienceDirect (Elsevier)</source><creator>Hu, Mengci ; Li, Wenzhe ; Zhang, Youshan ; Liang, Caixia ; Tan, Jie ; Wang, Ya</creator><creatorcontrib>Hu, Mengci ; Li, Wenzhe ; Zhang, Youshan ; Liang, Caixia ; Tan, Jie ; Wang, Ya</creatorcontrib><description>Venetoclax is a potent inhibitor that specifically targets B-cell lymphoma-2 (BCL-2), which has been demonstrated to be effective in preclinical studies utilizing acute myeloid leukemia (AML) cell lines and xenograft models. Significant antileukemic activity was also observed in clinical trials, both as a monotherapy and in combination with other drugs. This novel therapeutic approach has revolutionized the treatment prospects for AML patients with unfavorable prognoses and those who are unable to tolerate intensive chemotherapy. Nevertheless, further investigations are required to establish the optimal dosing, sequencing, and combinational strategies of venetoclax for AML treatments. Additionally, identifying biomarkers is crucial for predicting response and resistance to this targeted intervention. In this review, we provide an overview of venetoclax-based therapy for AML and explore potential avenues for future research.</description><identifier>ISSN: 0753-3322</identifier><identifier>EISSN: 1950-6007</identifier><identifier>DOI: 10.1016/j.biopha.2023.115820</identifier><language>eng</language><publisher>Elsevier Masson SAS</publisher><subject>Acute myeloid leukemia ; Combinatorial regimens ; Venetoclax</subject><ispartof>Biomedicine &amp; pharmacotherapy, 2023-12, Vol.168, p.115820-115820, Article 115820</ispartof><rights>2023 The Authors</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c385t-8ed44685a0b3b41fb866466c35af8367e7015ab862c4cde5db7a8d3c4bd2c68c3</citedby><cites>FETCH-LOGICAL-c385t-8ed44685a0b3b41fb866466c35af8367e7015ab862c4cde5db7a8d3c4bd2c68c3</cites><orcidid>0009-0003-6535-2779</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.biopha.2023.115820$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids></links><search><creatorcontrib>Hu, Mengci</creatorcontrib><creatorcontrib>Li, Wenzhe</creatorcontrib><creatorcontrib>Zhang, Youshan</creatorcontrib><creatorcontrib>Liang, Caixia</creatorcontrib><creatorcontrib>Tan, Jie</creatorcontrib><creatorcontrib>Wang, Ya</creatorcontrib><title>Venetoclax in adult acute myeloid leukemia</title><title>Biomedicine &amp; pharmacotherapy</title><description>Venetoclax is a potent inhibitor that specifically targets B-cell lymphoma-2 (BCL-2), which has been demonstrated to be effective in preclinical studies utilizing acute myeloid leukemia (AML) cell lines and xenograft models. Significant antileukemic activity was also observed in clinical trials, both as a monotherapy and in combination with other drugs. This novel therapeutic approach has revolutionized the treatment prospects for AML patients with unfavorable prognoses and those who are unable to tolerate intensive chemotherapy. Nevertheless, further investigations are required to establish the optimal dosing, sequencing, and combinational strategies of venetoclax for AML treatments. Additionally, identifying biomarkers is crucial for predicting response and resistance to this targeted intervention. In this review, we provide an overview of venetoclax-based therapy for AML and explore potential avenues for future research.</description><subject>Acute myeloid leukemia</subject><subject>Combinatorial regimens</subject><subject>Venetoclax</subject><issn>0753-3322</issn><issn>1950-6007</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kE1LxDAYhIMouK7-Aw89itCa72Yvgix-wYIX9RrS5C1mTZs1acX993apZ08Dw8zAPAhdElwRTOTNtmp83H2YimLKKkKEovgILchK4FJiXB-jBa4FKxmj9BSd5bzFGAvJ1AJdv0MPQ7TB_BS-L4wbw1AYOw5QdHsI0bsiwPgJnTfn6KQ1IcPFny7R28P96_qp3Lw8Pq_vNqVlSgylAse5VMLghjWctI2SkktpmTCtYrKGGhNhJpdabh0I19RGOWZ546iVyrIlupp3dyl-jZAH3flsIQTTQxyzpkpJsVKUr6Yon6M2xZwTtHqXfGfSXhOsD2j0Vs9o9AGNntFMtdu5BtONbw9JZ-uht-B8AjtoF_3_A7-nCG2O</recordid><startdate>202312</startdate><enddate>202312</enddate><creator>Hu, Mengci</creator><creator>Li, Wenzhe</creator><creator>Zhang, Youshan</creator><creator>Liang, Caixia</creator><creator>Tan, Jie</creator><creator>Wang, Ya</creator><general>Elsevier Masson SAS</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0009-0003-6535-2779</orcidid></search><sort><creationdate>202312</creationdate><title>Venetoclax in adult acute myeloid leukemia</title><author>Hu, Mengci ; Li, Wenzhe ; Zhang, Youshan ; Liang, Caixia ; Tan, Jie ; Wang, Ya</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c385t-8ed44685a0b3b41fb866466c35af8367e7015ab862c4cde5db7a8d3c4bd2c68c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Acute myeloid leukemia</topic><topic>Combinatorial regimens</topic><topic>Venetoclax</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hu, Mengci</creatorcontrib><creatorcontrib>Li, Wenzhe</creatorcontrib><creatorcontrib>Zhang, Youshan</creatorcontrib><creatorcontrib>Liang, Caixia</creatorcontrib><creatorcontrib>Tan, Jie</creatorcontrib><creatorcontrib>Wang, Ya</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biomedicine &amp; pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hu, Mengci</au><au>Li, Wenzhe</au><au>Zhang, Youshan</au><au>Liang, Caixia</au><au>Tan, Jie</au><au>Wang, Ya</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Venetoclax in adult acute myeloid leukemia</atitle><jtitle>Biomedicine &amp; pharmacotherapy</jtitle><date>2023-12</date><risdate>2023</risdate><volume>168</volume><spage>115820</spage><epage>115820</epage><pages>115820-115820</pages><artnum>115820</artnum><issn>0753-3322</issn><eissn>1950-6007</eissn><abstract>Venetoclax is a potent inhibitor that specifically targets B-cell lymphoma-2 (BCL-2), which has been demonstrated to be effective in preclinical studies utilizing acute myeloid leukemia (AML) cell lines and xenograft models. Significant antileukemic activity was also observed in clinical trials, both as a monotherapy and in combination with other drugs. This novel therapeutic approach has revolutionized the treatment prospects for AML patients with unfavorable prognoses and those who are unable to tolerate intensive chemotherapy. Nevertheless, further investigations are required to establish the optimal dosing, sequencing, and combinational strategies of venetoclax for AML treatments. Additionally, identifying biomarkers is crucial for predicting response and resistance to this targeted intervention. In this review, we provide an overview of venetoclax-based therapy for AML and explore potential avenues for future research.</abstract><pub>Elsevier Masson SAS</pub><doi>10.1016/j.biopha.2023.115820</doi><tpages>1</tpages><orcidid>https://orcid.org/0009-0003-6535-2779</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0753-3322
ispartof Biomedicine & pharmacotherapy, 2023-12, Vol.168, p.115820-115820, Article 115820
issn 0753-3322
1950-6007
language eng
recordid cdi_proquest_miscellaneous_2886598249
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Access via ScienceDirect (Elsevier)
subjects Acute myeloid leukemia
Combinatorial regimens
Venetoclax
title Venetoclax in adult acute myeloid leukemia
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T01%3A29%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Venetoclax%20in%20adult%20acute%20myeloid%20leukemia&rft.jtitle=Biomedicine%20&%20pharmacotherapy&rft.au=Hu,%20Mengci&rft.date=2023-12&rft.volume=168&rft.spage=115820&rft.epage=115820&rft.pages=115820-115820&rft.artnum=115820&rft.issn=0753-3322&rft.eissn=1950-6007&rft_id=info:doi/10.1016/j.biopha.2023.115820&rft_dat=%3Cproquest_cross%3E2886598249%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2886598249&rft_id=info:pmid/&rft_els_id=S0753332223016189&rfr_iscdi=true